



## Respiratory Pathogens Data Sep 14 - Dec 21 2018

Week Beginning	InfA-H1	InfA-H3	2009 H1N1	Inf B	RSV	All Para	EV/ Rhino	Meta pneumo	Adeno	All Corona	Bocca	Mycoplasma	Chlamydia	Total Pos	POS FLU	Total	ACL %FLU	US %FLU	IL/WI PCR	Sofia EIA
DEC 21	0	2	13	0	105	19	72	10	8	21	10	1	0	261	15	766	2.0	n/a	n/a	7.2
DEC 14	0	0	4	0	55	22	54	3	8	6	6	2	0	160	4	891	0.4	11.0	4.1	5.1
DEC 7	0	0	2	0	63	26	58	9	10	8	2	3	2	183	2	785	0.3	3.6	1.8	1.8
Nov 30	0	0	1	0	42	25	71	9	8	9	5	4	1	175	4	641	0.6	4.2	1.9	1.9
NOV 23	0	2	2	0	51	29	83	5	10	4	3	4	0	193	4	566	0.7	2.4	1.6	2.7
NOV 16	1	0	0	0	25	29	92	3	5	1	4	4	0	164	1	457	0.2	1.7	1.5	0.7
NOV 9	0	0	1	0	23	28	78	4	7	5	1	6	2	155	1	458	0.2	1.2	0.9	1.5
OCT 26	0	0	2	0	18	23	93	1	8	2	3	6	1	157	2	506	0.4	0.9	0.7	1.6
OCT 19	0	0	1	0	12	25	93	1	5	3	3	6	0	149	1	415	0.2	0.8	0.5	1.3
OCT 12	0	0	0	0	11	17	111	1	4	3	0	1	1	149	0	478	0.0	0.6	0.4	1.0
OCT 6	0	0	1	0	4	15	101	2	5	1	2	2	0	133	1	435	0.2	0.8	0.5	1.5
SEP 28	0	0	0	0	1	10	103	2	1	2	2	3	0	124	0	410	0.0	0.9	0.6	1.5
SEP 21	0	0	0	0	1	10	107	1	6	3	3	0	2	133	0	388	0.0	0.8	0.9	0.9
SEP 14	0	0	0	0	2	9	135	0	2	0	5	1	0	154	0	415	0.0	0.7	1.0	0.7



Flu PCR  
% Rate



### ACL RESP. PANEL - RSV PCR - 14%, RSV EIA - 11%



### ACL RESP. PANEL - Flu PCR - 2.0%, Flu EIA - 7.2%



## Correlation between RPPNL (FLU PCR) and Sofia (FLUAG)


Accuracy for the beginning of the season is 99.3%

In the last six weeks 686 samples were tested by both methods most of them negative, 11 samples were positive by EIA and 7 of them were confirmed by PCR. One samples was negative by EIA and was tested positive by PCR method

Nov 11 2018 to Dec 21 2018				
FLUAG (Sofia) vs RPPNL (PCR) correlation				
		RPPNL		
		+	-	Total
FluAG	+	7	4	11
	-	1	674	675
		Total		686
%				
87.5	Clinical Sensitivity			
99.4	Clinical Specificity			
63.6	Positive Predictive Value (PPV)			
99.9	Negative Predictive Value (NPV)			
99.3	Accuracy			

Dec 15, 2018 **Positivity rate 11%** - Flu A – 95% , Flu B – 5%


### Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2018-2019 Season



## A Weekly Influenza Surveillance Report Prepared by the Influenza Division


### Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists\*

Week Ending Dec 15, 2018 - Week 50




\*This map indicates geographic spread and does not measure the severity of influenza activity.

## 2018-19 Influenza Season Week 50 ending Dec 15, 2018



### ILI Activity Level



\*This map uses the proportion of outpatient visits to healthcare providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.


\*Data collected in ILINet may disproportionately represent certain populations within a state, and therefore may not accurately depict the full picture of influenza activity for the whole state.

\*Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map are based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received.

\*Differences in the data presented by CDC and state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.


\*For the data download you can use Activity Level for the number and Activity Level Label for the text description.

The most prevalent target as Dec 7th was HSV2 – total pos. rate 6.4%







The most prevalent targets as Dec 7<sup>th</sup> was **Giardia**



The most prevalent target as Dec 7<sup>th</sup> was Norovirus



	BV-Bacterial vagionosis	Candida albicans	Candida galbrata	Candida kruzei	T. vaginalis	M. genitalium	M. hominis	U. parvum	TOTAL % POS
% pos	<b>21.9</b>	<b>13.2</b>	<b>1.9</b>	<b>0.3</b>	<b>3.1</b>	<b>0.1</b>	<b>6.7</b>	<b>18.8</b>	<b>66.0</b>



## Neuraminidase Inhibitors Resistance in Samples Collected – as of Dec 15, 2018,

Per CDC website	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)	Virus Samples tested (n)	Resistant Viruses, (%)
Influenza A (H1N1)pdm09	<b>161</b>	<b>0</b>	<b>161</b>	<b>0</b>	<b>161</b>	<b>0</b>
Influenza A (H3N2)	<b>68</b>	<b>0</b>	<b>68</b>	<b>0</b>	<b>68</b>	<b>0</b>
Influenza B	<b>28</b>	<b>0</b>	<b>28</b>	<b>0</b>	<b>28</b>	<b>0</b>